Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015–2023: a population-based, real-world study

The use of antipsychotics (APs) in children and adolescents has increased notably worldwide, often beyond approved indications. However, most real-world studies lack direct information on the clinical reasons for prescribing. In this population-based study conducted in the region of Valencia, Spain, we analysed 128,057 AP treatments, comprising 741,213 prescriptions, issued to 30,383 individuals aged 0-19 years between 2015 and 2023, using real-world data that uniquely includes prescriber-recorded indications. We described the distribution and temporal evolution of the number of AP treatments by indication, age, sex, and active substance. The most frequent indications were disorders of personality and behaviour (20.2% of treatments), attention-deficit/hyperactivity disorder (14.2%), autism spectrum disorders (13.9%), anxiety-related disorders (11.4%), and psychotic disorders (5.8%). Among the most frequent indications, depression treatments showed the steepest increase (5.7-fold). Sharp rises also were observed for suicidal ideation (30.7-fold), psychoactive drug use (2.8-fold), eating disorders (2.3-fold), and autism-related conditions (2.2-fold). Changes were more pronounced in females and older adolescents, particularly after 2020. The number of ADHD treatments declined substantially over time. Sulpiride was almost exclusively prescribed for dizziness, a non-psychiatric but approved indication in adults in Spain. Our findings align with international trends but provide greater specificity thanks to the direct link between prescriptions and indications. This study highlights an increase in the volume of AP treatments in paediatric populations, mostly in non-approved, and potentially high-risk indications, some of which have not been previously documented. Our results underscore the need for close monitoring and further evaluation of the appropriateness and safety of antipsychotic prescription in the youth.

Authors

Institutions

Publication Details

Journal
European Child & Adolescent Psychiatry
Published
2025-10-15
DOI
https://doi.org/10.1007/s00787-025-02875-7
Citations
1
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015–2023: a population-based, real-world study

Aníbal García‐Sempere, Salvador Peiró, Anna Lluch Oltra, Inmaculada Baeza et al.
1 citations
European Child & Adolescent Psychiatry
Attention Deficit Hyperactivity Disorder
1.47
article

Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015–2023: a population-based, real-world study

Aníbal García‐Sempere, Salvador Peiró, Anna Lluch Oltra, Inmaculada Baeza, Isabel Hurtado, Verónica Gamón, Gabriel Sanfélix‐Gimeno, Clara Liliana Rodríguez-Bernal, Fran Llopis-Cardona, Rafael Tabarés‐Seisdedos, Celia Robles-Cabaniñas, María Fernanda Carrillo-Arenas
article en
1 citations

Abstract

The use of antipsychotics (APs) in children and adolescents has increased notably worldwide, often beyond approved indications. However, most real-world studies lack direct information on the clinical reasons for prescribing. In this population-based study conducted in the region of Valencia, Spain, we analysed 128,057 AP treatments, comprising 741,213 prescriptions, issued to 30,383 individuals aged 0-19 years between 2015 and 2023, using real-world data that uniquely includes prescriber-recorded indications. We described the distribution and temporal evolution of the number of AP treatments by indication, age, sex, and active substance. The most frequent indications were disorders of personality and behaviour (20.2% of treatments), attention-deficit/hyperactivity disorder (14.2%), autism spectrum disorders (13.9%), anxiety-related disorders (11.4%), and psychotic disorders (5.8%). Among the most frequent indications, depression treatments showed the steepest increase (5.7-fold). Sharp rises also were observed for suicidal ideation (30.7-fold), psychoactive drug use (2.8-fold), eating disorders (2.3-fold), and autism-related conditions (2.2-fold). Changes were more pronounced in females and older adolescents, particularly after 2020. The number of ADHD treatments declined substantially over time. Sulpiride was almost exclusively prescribed for dizziness, a non-psychiatric but approved indication in adults in Spain. Our findings align with international trends but provide greater specificity thanks to the direct link between prescriptions and indications. This study highlights an increase in the volume of AP treatments in paediatric populations, mostly in non-approved, and potentially high-risk indications, some of which have not been previously documented. Our results underscore the need for close monitoring and further evaluation of the appropriateness and safety of antipsychotic prescription in the youth.

European Child & Adolescent Psychiatry
Universitat de València (ES), Neurosciences Institute (US), Instituto de Salud Carlos III (ES), Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES), Red de Investigación en Actividades Preventivas y Promoción de la Salud (ES), Hospital Clínic de Barcelona (ES), Fundació Clínic per a la Recerca Biomèdica (ES), INCLIVA Health Research Institute (ES), Medical Research Network (US), Universitat de Barcelona (ES)
Openalex Percentile: Top 14%
Attention Deficit Hyperactivity Disorder
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.